- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma
December 6th 2025, 8:00pm
ASH Annual Meeting and Exposition
Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.
Dr Li on Progression Risk in Low-Grade NMIBC and the Emerging Role of AI-Based Pathology Assessment
December 6th 2025, 7:46pm
Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.
Survival in Induction Chemotherapy AML Studies May be Predictable by MRD
December 6th 2025, 7:15pm
ASH Annual Meeting and Exposition
Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.
Race Is Predictive of Survival Outcomes With Intensive Chemotherapy Independent of Cytogenetics in AML
December 6th 2025, 7:15pm
ASH Annual Meeting and Exposition
Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.
Lisaftoclax Displays Activity in R/R CLL/SLL
December 6th 2025, 7:03pm
ASH Annual Meeting and Exposition
Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.
BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL
December 6th 2025, 6:48pm
ASH Annual Meeting and Exposition
In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.
Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression
December 6th 2025, 6:45pm
ASH Annual Meeting and Exposition
Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.
Families Face Financial Hardships in Pediatric ALL
December 6th 2025, 5:45pm
ASH Annual Meeting and Exposition
Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.
Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma
December 6th 2025, 5:44pm
ASH Annual Meeting and Exposition
Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.
Venetoclax-Based, Fixed-Duration Regimens Match Continuous Ibrutinib in Frontline CLL
December 6th 2025, 5:31pm
ASH Annual Meeting and Exposition
Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.
TBI-Free Conditioning Maintains Strong Outcomes in Pediatric and Young Adult B-Cell ALL
December 6th 2025, 5:19pm
ASH Annual Meeting and Exposition
The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.
Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC
December 6th 2025, 4:19pm
Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.
Intravesical Cretostimogene Grenadenorepvec Is Active in BCG-Naive High-Risk NMIBC
December 6th 2025, 3:56pm
Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.
Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC
December 6th 2025, 4:01am
Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.
Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC
December 6th 2025, 2:00am
Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.
Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age
December 6th 2025, 1:56am
Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.
Experts Prepare for Several Key MCL Presentations at ASH 2025
December 5th 2025, 11:31pm
ASH Annual Meeting and Exposition
Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer
December 5th 2025, 9:22pm
Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.
Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years
December 5th 2025, 8:39pm
At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.
Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer
December 5th 2025, 6:08pm
Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.